Mycophenolsäure Stada (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsäure Stada, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to reduce the risk of organ transplant rejection and to manage certain autoimmune diseases such as lupus nephritis by suppressing lymphocyte proliferation.

GNH USA supplies Mycophenolsäure Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to WHO‑GMP standards and provides reliable logistics for regulated markets, and ensures timely delivery.

Mycophenolic Acid is used in immunosuppressive therapy targeting lymphocyte proliferation.

Organ transplant rejection: helps prevent rejection of transplanted organs by suppressing immune response. Lupus nephritis: reduces kidney inflammation in systemic lupus erythematosus. Kidney transplant: maintains graft function after renal transplantation. Other autoimmune diseases: employed in selected autoimmune conditions such as vasculitis.

Adverse reactions may occur with Mycophenolic Acid therapy.

Common Side Effects: - Nausea - Diarrhea - Headache - Abdominal pain

Serious or Rare Side Effects: - Bone marrow suppression (leukopenia, anemia) - Severe infections (including opportunistic pathogens) - Liver toxicity (elevated transaminases) - Progressive multifocal leukoencephalopathy (PML)

Use of Mycophenolic Acid requires careful monitoring and patient education. - Blood count monitoring: perform regular CBC to detect leukopenia or anemia. - Liver function monitoring: assess hepatic enzymes periodically. - Renal function assessment: adjust dose in impaired kidney function. - Vaccination caution: avoid live vaccines during therapy. - Pregnancy considerations: use only if benefits outweigh risks; consult specialist. - Store at below 25°C: keep in original packaging, protect from moisture.

Mycophenolic Acid can interact with several medicines, necessitating clinical vigilance.

Major Interactions (Avoid): - Azathioprine: combined use markedly increases bone marrow toxicity. - Live vaccines: may cause severe infection; avoid administration.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Cyclosporine or tacrolimus: may increase mycophenolic acid levels, adjust dose as needed. - Cholestyramine: reduces absorption of mycophenolic acid, separate administration times.